Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Operating Expenses | 4,290 | 5,668 | 4,471 | -8,744 | 6,472 |
| Operating Income | -4,290 | -5,668 | -4,471 | 8,744 | -6,472 |
| Interest Expense | 102 | 0 | 130 | -821 | 1,377 |
| Other Income | 0 | -128 | 0 | -18,079 | 3,507 |
| Pre-tax Income | -4,392 | -5,796 | -4,601 | -8,514 | -4,342 |
| Income Tax | 63 | 117 | N/A | N/A | N/A |
| Net Income Continuous | -4,455 | -5,913 | -4,601 | -8,515 | -4,342 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -2,587 |
| Net Income | $-4,455 | $-5,913 | $-4,601 | $352 | $-6,929 |
| EPS Basic Total Ops | -113.50 | -225.00 | -181.50 | 1,934.87 | -990.99 |
| EPS Basic Continuous Ops | -113.47 | -225.17 | -181.43 | 507.91 | -615.62 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | -375.38 |
| EPS Diluted Total Ops | -113.50 | -225.00 | -181.50 | 1,949.88 | -990.99 |
| EPS Diluted Continuous Ops | -113.47 | -225.17 | -181.43 | 522.93 | -615.62 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | -375.38 |
| EBITDA(a) | $-4,263 | $-5,668 | $-4,471 | $8,652 | $-6,442 |